Developer of gene therapies for rare diseases. The therapies are developed for the treatment of Duchenne muscular dystrophy and type 1 diabetes. The company has a non-viral gene delivery platform 3DNA that delivers genes of all sizes, improves cellular targeting, and reduces immunogenicity. Founded in 2020, headquartered in Hatfield, United States. The company has raised $85.0M in funding at the series a stage. The team comprises 22 (Jun 30, 2026) employees. The company operates in the Genomics sector with additional focus on Gene Therapy and Rare Diseases. Its business model centers on Muscle Disorders. Founded in 2020, headquartered in Hatfield, United States. The company has raised $85.0M at the Series A stage. Backed by investors including 4Bio Capital, UPMC, Takeda, New Enterprise Associates, T1D Fund and others.
Code Biotherapeutics
Series ADeveloper of gene therapies for rare diseases. The therapies are developed for the treatment of Duchenne muscular dystrophy and type 1 diabetes. The company has a non-viral gene delivery platform 3DNA that delivers genes of all sizes, improves cellular targeting, and reduces immunogenicity. Founded in 2020, headquartered in Hatfield, United States. The company has raised $85.0M in funding at the series a stage. The…
About
Business model
Orthopedics > Drugs > Muscle Disorders,
Rare Diseases > Drugs > Musculoskeletal,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.
Similar startups
Raising like Code Biotherapeutics?
Analyze your pitch deck before your next raise.
Analyze My Deck →